Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions

Overview

Journal Ann Am Thorac Soc

Specialty Pulmonary Medicine

Date 2015 Dec 10

PMID 26646726

Citations 52

Authors

Gal Shafirstein

Athar Battoo

Kassem Harris

Heinz Baumann

Sandra O Gollnick

Joerg Lindenmann

Chukwumere E Nwogu

Affiliations

Soon will be listed here.

Abstract

Photodynamic therapy (PDT) is an established treatment modality for non-small cell lung cancer. Phototoxicity, the primary adverse event, is expected to be minimized with the introduction of new photosensitizers that have shown promising results in phase I and II clinical studies. Early-stage and superficial endobronchial lesions less than 1 cm in thickness can be effectively treated with external light sources. Thicker lesions and peripheral lesions may be amenable to interstitial PDT, where the light is delivered intratumorally. The addition of PDT to standard-of-care surgery and chemotherapy can improve survival and outcomes in patients with pleural disease. Intraoperative PDT has shown promise in the treatment of non-small cell lung cancer with pleural spread. Recent preclinical and clinical data suggest that PDT can increase antitumor immunity. Crosslinking of signal transducer and activator of transcription-3 molecules is a reliable biomarker to quantify the photoreaction induced by PDT. Randomized studies are required to test the prognosis value of this biomarker, obtain approval for the new photosensitizers, and test the potential efficacy of interstitial and intraoperative PDT in the treatment of patients with non-small cell lung cancer.

Citing Articles

Photosynthetic Bacteria: Light-Responsive Biomaterials for Anti-Tumor Photodynamic Therapy.

Jiang Y Int J Nanomedicine. 2025; 20():465-482.

PMID: 39811429 PMC: 11730521. DOI: 10.2147/IJN.S500314.

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?.

Pagliari G, Colonese F, Canova S, Abbate M, Sala L, Petrella F Cancers (Basel). 2024; 16(23).

PMID: 39682081 PMC: 11639858. DOI: 10.3390/cancers16233892.

Development of a protocol for whole-lung lung perfusion-assisted photodynamic therapy using a porcine model.

Ramadan K, Saeidi T, Brambate E, Bagnato V, Cypel M, Lilge L J Biomed Opt. 2024; 29(11):118001.

PMID: 39552752 PMC: 11563932. DOI: 10.1117/1.JBO.29.11.118001.

Cetuximab-Toxin Conjugate and NPe6 with Light Enhanced Cytotoxic Effects in Head and Neck Squamous Cell Carcinoma In Vitro.

Komatsu N, Kosai A, Kuroda M, Hamakubo T, Abe T Biomedicines. 2024; 12(5).

PMID: 38790935 PMC: 11117702. DOI: 10.3390/biomedicines12050973.

Enhanced cellular therapy: revolutionizing adoptive cellular therapy.

Xu M, Zeng N, Liu C, Sun J, An Y, Zhang S Exp Hematol Oncol. 2024; 13(1):47.

PMID: 38664743 PMC: 11046957. DOI: 10.1186/s40164-024-00506-6.

References

Henderson B, Bellnier D, Greco W, Sharma A, Pandey R, Vaughan L . An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res. 1997; 57(18):4000-7. View

Rusch V, Hawes D, Decker P, Martin S, Abati A, Landreneau R . Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011; 29(32):4313-9. PMC: 3221530. DOI: 10.1200/JCO.2011.35.2500. View

Lim E, Clough R, Goldstraw P, Edmonds L, Aokage K, Yoshida J . Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: An international individual patient data meta-analysis. J Thorac Cardiovasc Surg. 2009; 139(6):1441-6. DOI: 10.1016/j.jtcvs.2009.05.048. View

Rigual N, Shafirstein G, Cooper M, Baumann H, Bellnier D, Sunar U . Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin Cancer Res. 2013; 19(23):6605-13. PMC: 3911775. DOI: 10.1158/1078-0432.CCR-13-1735. View

Edmonds C, Hagan S, Gallagher-Colombo S, Busch T, Cengel K . Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer Biol Ther. 2012; 13(14):1463-70. PMC: 3542238. DOI: 10.4161/cbt.22256. View

Li J, Chen Y, Zhao S, Zhang L, Song S . Application of hematoporphyrin derivative and laser-induced photodynamical reaction in the treatment of lung cancer: a preliminary report on 21 cases. Lasers Surg Med. 1984; 4(1):31-7. DOI: 10.1002/lsm.1900040105. View

Banerjee A, George J . Bronchoscopic photodynamic diagnosis and therapy for lung cancer. Curr Opin Pulm Med. 2000; 6(4):378-83. DOI: 10.1097/00063198-200007000-00021. View

Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A . Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother. 2008; 58(1):71-84. PMC: 11030999. DOI: 10.1007/s00262-008-0527-0. View

Krammer B . Vascular effects of photodynamic therapy. Anticancer Res. 2002; 21(6B):4271-7. View

10.

Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N . A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol. 1993; 11(10):1852-7. DOI: 10.1200/JCO.1993.11.10.1852. View

11.

Arsenev A, Kanaev S, Barchuk A, Vedenin I, Klitenko V, Gelfond M . [Use of endotracheobronchial surgery in conjunction with radiochemotherapy for advanced non-small lung cancer]. Vopr Onkol. 2007; 53(4):461-7. View

12.

Davidson S, Weersink R, Haider M, Gertner M, Bogaards A, Giewercer D . Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol. 2009; 54(8):2293-313. DOI: 10.1088/0031-9155/54/8/003. View

13.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

14.

Furukawa K, Kato H, Konaka C, Okunaka T, Usuda J, Ebihara Y . Locally recurrent central-type early stage lung cancer < 1.0 cm in diameter after complete remission by photodynamic therapy. Chest. 2005; 128(5):3269-75. DOI: 10.1378/chest.128.5.3269. View

15.

LoCicero 3rd J, Metzdorff M, Almgren C . Photodynamic therapy in the palliation of late stage obstructing non-small cell lung cancer. Chest. 1990; 98(1):97-100. DOI: 10.1378/chest.98.1.97. View

16.

Lipson E, Sharfman W, Drake C, Wollner I, Taube J, Anders R . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2012; 19(2):462-8. PMC: 3548952. DOI: 10.1158/1078-0432.CCR-12-2625. View

17.

Ross Jr P, Grecula J, Bekaii-Saab T, Villalona-Calero M, Otterson G, Magro C . Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg Med. 2006; 38(10):881-9. DOI: 10.1002/lsm.20444. View

18.

Swartling J, Axelsson J, Ahlgren G, Kalkner K, Nilsson S, Svanberg S . System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer. J Biomed Opt. 2010; 15(5):058003. DOI: 10.1117/1.3495720. View

19.

Reginato E, Mroz P, Chung H, Kawakubo M, Wolf P, Hamblin M . Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer. 2013; 109(8):2167-74. PMC: 3798975. DOI: 10.1038/bjc.2013.580. View

20.

Brackett C, Gollnick S . Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci. 2011; 10(5):649-52. PMC: 3197776. DOI: 10.1039/c0pp00354a. View